Does anti-EGFR therapy improve outcome in advanced colorectal cancer? A systematic review and meta-analysis.

Does anti-EGFR therapy improve outcome in advanced colorectal cancer? A systematic review and meta-analysis.

Show other versions (1)

BACKGROUND: Randomised controlled trials (RCTs) of anti-EGFR monoclonal antibodies (MAb) in patients with advanced colorectal cancer (aCRC) have reported conflicting results. METHODS: A systematic review of RCTs comparing standard treatments±anti-EGFR MAbs was conducted. Hazard ratios (HR) for progr...

Full description

Bibliographic Details
Main Authors:	Vale, C, Tierney, J, Fisher, D, Adams, R, Kaplan, R, Maughan, T, Parmar, M, Meade, A
Format:	Journal article
Language:	English
Published:	2012

Similar Items

Does anti-EGFR therapy improve outcome in advanced colorectal cancer? A systematic review and meta-analysis
by: Vale, C, et al.
Published: (2012)

A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMISED CONTROLLED TRIALS (RCTS) OF EGFR-TARGETED MONOCLONAL ANTIBODY (MAB) THERAPY IN ADVANCED COLORECTAL CANCER (ACRC): IMPACT OF K-RAS STATUS
by: Vale, C, et al.
Published: (2009)

Impact of K-ras status on the effects of EGFR-targeted monoclonal antibody (MAb) therapy in advanced colorectal cancer (ACRC): A systematic review and meta-analysis of randomized controlled trials (RCTs)
by: Vale, C, et al.
Published: (2009)

THROMBOCYTOSIS AS A PREDICTIVE AND PROGNOSTIC MARKER IN ADVANCED COLORECTAL CANCER (ACRC): RESULTS OF THE MRC COIN TRIAL EXPLORED
by: Maughan, T, et al.
Published: (2010)

Oxaliplatin/capecitabine vs oxaliplatin/infusional 5-FU in advanced colorectal cancer: the MRC COIN trial.
by: Madi, A, et al.
Published: (2012)

Oxaliplatin/capecitabine vs oxaliplatin/infusional 5-FU in advanced colorectal cancer: The MRC COIN trial
by: Madi, A, et al.
Published: (2012)

HIGH THROUGHPUT SOMATIC PROFILING OF THE RAS-RAF-MAP AND PI3K-PTEN-AKT PATHWAYS IN ADVANCED COLORECTAL CANCER AND CORRELATIONS WITH RESPONSE TO CETUXIMAB
by: Smith, C, et al.
Published: (2010)

Intermittent versus continuous oxaliplatin-based combination chemotherapy in patients with advanced colorectal cancer: a randomised non-inferiority trial (MRC COIN)
by: Adams, R, et al.
Published: (2009)

Chemotherapy-free intervals for patients with metastatic colorectal cancer remain an option.
by: Maughan, T, et al.
Published: (2010)

INTERMITTENT VS. CONTINUOUS OXALIPLATIN-FLUOROPYRIMIDINE CHEMOTHERAPY IN THE MRC COIN TRIAL IN ADVANCED COLORECTAL CANCER: UPDATED EFFICACY RESULTS, QUALITY OF LIFE AND POTENTIAL PREDICTIVE FACTORS
by: Adams, R, et al.
Published: (2010)

THE ADDITION OF CETUXIMAB TO OXALIPLATIN-FLUOROPYRIMIDINE CHEMOTHERAPY IN FIRST-LINE ADVANCED COLORECTAL CANCER IN THE MRC COIN TRIAL: IDENTIFICATION OF POTENTIALLY RESPONSIVE SUBSETS OF PATIENTS
by: Maughan, T, et al.
Published: (2010)

Addition of cetuximab to oxaliplatin-based combination chemotherapy (CT) in patients with KRAS wild-type advanced colorectal cancer (ACRC): a randomised superiority trial (MRC COIN)
by: Maughan, T, et al.
Published: (2009)

Pharmacogenetic analyses of 2183 patients with advanced colorectal cancer; potential role for common dihydropyrimidine dehydrogenase variants in toxicity to chemotherapy
by: Madi, A, et al.
Published: (2018)

Derived neutrophil to lymphocyte ratio as a prognostic factor in patients with advanced colorectal cancer according to RAS and BRAF status: a post-hoc analysis of the MRC COIN study.
by: Wood, G, et al.
Published: (2017)

Somatic profiling of the epidermal growth factor receptor pathway in tumors from patients with advanced colorectal cancer treated with chemotherapy ± cetuximab.
by: Smith, C, et al.
Published: (2013)

Circulating Tumor DNA Detection in the Management of Anti-EGFR Therapy for Advanced Colorectal Cancer
by: Franciele H. Knebel, et al.
Published: (2019-03-01)

Cetuximab therapy in first-line metastatic colorectal cancer and intermittent palliative chemotherapy: review of the COIN trial.
by: Adams, R, et al.
Published: (2008)

A NOVEL COLORECTAL CANCER SUSCEPTIBILITY SNP IN THE EIF3H PROMOTER INFLUENCES PATIENT SURVIVAL AND RESPONSE TO TREATMENT
by: Cheadle, J, et al.
Published: (2010)

Fc gamma receptor IIIa polymorphisms in advanced colorectal cancer patients correlated with response to anti-EGFR antibodies and clinical outcome
by: Calemma Rosa, et al.
Published: (2012-11-01)

Intermittent Chemotherapy (CT) Plus Continuous or Intermittent Cetuximab (C) in the First-line Treatment of Advanced Colorectal Cancer (aCRC): Results of the Two-arm Phase II Randomised MRC COIN-B Trial
by: Wasan, H, et al.
Published: (2011)

<it>EGFR</it> gene copy number as a predictive biomarker for the treatment of metastatic colorectal cancer with anti-EGFR monoclonal antibodies: a meta-analysis
by: Yang Zu-Yao, et al.
Published: (2012-08-01)

Prediction of response to anti-EGFR antibodies in metastatic colorectal cancer: looking beyond EGFR inhibition.
by: Alessandro eOttaiano, et al.
Published: (2013-01-01)

ADDITION OF CETUXIMAB TO OXALIPLATIN-BASED COMBINATION CHEMOTHERAPY (CT) IN PATIENTS WITH K-ras WILD-TYPE ADVANCED COLORECTAL CANCER (ACRC): EFFECTS ON OVERALL SURVIVAL. MRC COIN (CR10) TRIAL RESULTS
by: Adams, R, et al.
Published: (2009)

Real‐world outcomes of anti‐EGFR therapy in advanced non–small cell lung cancer EGFR mutated in Peru
by: Marco Galvez‐Nino, et al.
Published: (2023-01-01)

MOLECULAR MARKERS OF SENSITIVITY AND RESISTANCE OF COLORECTAL CANCER TO ANTI-EGFR T
by: A. O. Ivantsov, et al.
Published: (2016-04-01)

Current concepts of anti-EGFR targeting in metastatic colorectal cancer
by: Bernhard Doleschal, et al.
Published: (2022-11-01)

Investigating the poor outcomes of BRAF-mutant advanced colorectal cancer: analysis from 2530 patients in randomised clinical trials
by: Seligmann, JF, et al.
Published: (2016)

Toxicity associated with combination oxaliplatin plus fluoropyrimidine with or without cetuximab in the MRC COIN trial experience.
by: Adams, R, et al.
Published: (2009)

Efficacy and safety of triplet chemotherapy plus anti-EGFR agents in metastatic colorectal cancer: a systematic review and meta-analysis
by: Qian Wu, et al.
Published: (2022-08-01)

Duplicated network meta-analysis in advanced prostate cancer: a case study and recommendations for change
by: David J. Fisher, et al.
Published: (2022-12-01)

Inhibition of EGFR, HER2, and HER3 signalling in patients with colorectal cancer wild-type for BRAF, PIK3CA, KRAS, and NRAS (FOCUS4-D): a phase 2–3 randomised trial
by: Adams, R, et al.
Published: (2017)

Predicting response to epidermal growth factor receptor-targeted therapy in colorectal cancer.
by: Adams, R, et al.
Published: (2007)

EGFR FISH analysis in colorectal cancer as a tool in selecting patients for antiEGFR monoclonal antibodies therapy
by: Mauro Moroni, et al.
Published: (2011-12-01)

Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial.
by: Adams, R, et al.
Published: (2011)

The prognostic role of BRAF mutation in metastatic colorectal cancer receiving anti-EGFR monoclonal antibodies: a meta-analysis.
by: Zi-Xu Yuan, et al.
Published: (2013-01-01)

EGFR-TKIs or EGFR-TKIs combination treatments for untreated advanced EGFR-mutated NSCLC: a network meta-analysis
by: Ao Liu, et al.
Published: (2024-11-01)

Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial.
by: Maughan, T, et al.
Published: (2011)

BRAF and NRAS locus-specific variants have different outcomes on survival to colorectal cancer
by: Summers, MG, et al.
Published: (2016)

Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial.
by: Seymour, M, et al.
Published: (2007)

Correction: EGFR-TKIs or EGFR-TKIs combination treatments for untreated advanced EGFR-mutated NSCLC: a network meta-analysis
by: Ao Liu, et al.
Published: (2025-01-01)